XML 62 R30.htm IDEA: XBRL DOCUMENT
v3.20.4

Quarterly Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.
| Three Months Ended
| March 31, 2020 |  | June 30, 2020 |  | September 30, 2020 |  | December 31, 2020 (1)
Total revenues | $ | 29,838 |  |  | $ | 30,424 |  |  | $ | 23,583 |  |  | $ | 19,333 |
Operating loss | (16,600) |  |  | (11,830) |  |  | (23,006) |  |  | (35,167) |
Loss from continuing operations | (20,846) |  |  | (15,709) |  |  | (27,536) |  |  | (39,682) |
Net loss attributable to Precigen | (55,998) |  |  | (43,354) |  |  | (29,508) |  |  | (41,661) |
Net loss from continuing operations attributable to Precigen per share, basic and diluted | $ | (0.13) |  |  | $ | (0.10) |  |  | $ | (0.17) |  |  | $ | (0.22) |
Net loss attributable to Precigen per share, basic and diluted | $ | (0.35) |  |  | $ | (0.26) |  |  | $ | (0.18) |  |  | $ | (0.23) |
(1)During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).
| Three Months Ended
| March 31, 2019 |  | June 30, 2019 |  | September 30, 2019 |  | December 31, 2019 (1)
Total revenues | $ | 22,585 |  |  | $ | 32,836 |  |  | $ | 18,299 |  |  | $ | 17,002 |
Operating loss | (41,855) |  |  | (21,508) |  |  | (34,702) |  |  | (68,724) |
Loss from continuing operations | (44,539) |  |  | (22,440) |  |  | (39,119) |  |  | (64,236) |
Net loss attributable to Precigen | (60,709) |  |  | (38,766) |  |  | (53,634) |  |  | (169,215) |
Net loss from continuing operations attributable to Precigen per share, basic and diluted | $ | (0.28) |  |  | $ | (0.14) |  |  | $ | (0.25) |  |  | $ | (0.41) |
Net loss attributable to Precigen per share, basic and diluted | $ | (0.40) |  |  | $ | (0.25) |  |  | $ | (0.35) |  |  | $ | (1.09) |
(1)During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration